Ironwood Pharmaceuticals Stock
Ironwood Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Thomas A. McCourt
- Employees
- 100
- Market cap
- $578 M
- IPO
- 03/02/2010
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for…
Ironwood Pharmaceuticals stock: price history
1D
-7.2%
1W
-8.4%
1M
-16.1%
6M
-21.0%
YTD
+3.9%
1Y
+125.8%
2Y
-22.2%
5Y
-74.4%
10Y
-74.8%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~78% stronger price swings than usual
Ask the agents about Ironwood Pharmaceuticals
Analyst assessment of Ironwood Pharmaceuticals
PRICE TARGET LOW
US$1.00
CONSENSUS
US$6.68
MEDIAN
US$5.00
PRICE TARGET HIGH
US$18.00
0
STRONG BUY
11
BUY
16
HOLD
3
SELL
0
STRONG SELL
30
TOTAL · Hold
As of: 26/02/2026
Ironwood Pharmaceuticals stock metrics
P/E
4.4
P/B
-3.58
EV/EBITDA
3.7
RETURN ON EQUITY
-31.7%
NET MARGIN
45.4%
DEBT/EQUITY
-2.45
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.3%
FLOAT SHARES
159,102,656
AVG. DAILY VOLUME (30D)
2,061,921
Insider transactions (SEC)
DENNER ALEXANDER J
Silber Jeffrey
Silver Ronald
McHugh Julie
McHugh Julie
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Ironwood Pharmaceuticals stock
What does Ironwood Pharmaceuticals do?
Ironwood Pharmaceuticals, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Thomas A. McCourt, the company employs around 100 people.
The IPO was on 03/02/2010; the stock trades on NASDAQ under the ticker IRWD.
What do analysts say about Ironwood Pharmaceuticals stock?
30 analysts rate the stock, the consensus is Hold (as of 26/02/2026).
The average price target is US$6.68, ranging from US$1.00 to US$18.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Ironwood Pharmaceuticals report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 78% stronger than usual.
Does Ironwood Pharmaceuticals pay a dividend?
No, Ironwood Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Ironwood Pharmaceuticals?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Ironwood Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ironwood Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.